eGenesis

eGenesis' stated goal is to make xenotransplantation a routine medical procedure. The company is a Cambridge, MA-basedMA-based startup that's using the gene-editing tool CRISPR to make pig organs viable for transplants into people.

eGenesis' stated goal is to make xenotransplantation a routine medical procedure. The company is a CambridgeCambridge, MA-based startup that's using the gene-editing tool CRISPR to make pig organs viable for transplants into people.

The company raised $38 million in March 2017 and is cofounded by Harvard geneticist George Church and Luhan YangLuhan Yang.. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERV.

The company raised $38 million in March 2017 and is cofounded by Harvard geneticist George ChurchGeorge Church and Luhan Yang. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERV.

The company raised $38 million in March 2017 and is cofounded by HarvardHarvard geneticist George Church and Luhan Yang. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERV.

The company raised $38 million in March 20172017 and is cofounded by Harvard geneticist George Church and Luhan Yang. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERV.

The company raised $38 million in MarchMarch 2017 and is cofounded by Harvard geneticist George Church and Luhan Yang. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERV.

The company raised $38 million in March 2017 and is cofounded by Harvard geneticist George Church and Luhan Yang. Their research is focusing on removing certain genes in pigs that could cause diseases or organ rejection in humans, making it possible for those pig organs to be transplanted. eGenesis announced in the journal Science that it had produced 37 piglets that had inactivated Porcine Endogenous Retrovirus, or PERVPERV.